Coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
01 2022
Historique:
received: 21 10 2021
revised: 28 11 2021
accepted: 29 11 2021
pubmed: 21 12 2021
medline: 19 3 2022
entrez: 20 12 2021
Statut: ppublish

Résumé

To assess the relation between coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy. Cross-sectional analysis of data collected in the SAVE study, which included patients with drug-resistant focal epilepsy during long-term EEG monitoring. Patients in whom both coffee consumption and data about seizure frequency, including focal to bilateral tonic-clonic seizures (FBTCS), were available were selected. Coffee consumption was collected using a standardized self-report questionnaire and classified into four groups: none, rare (from less than 1 cup/week to up 3 cups/week), moderate (from 4 cups/week to 3 cups/day), and high (more than 4 cups/day). Six hundred and nineteen patients were included. There was no relation between coffee consumption and total seizure frequency (p = 0.902). In contrast, the number of FBTCS reported over the past year was significantly associated with usual coffee consumption (p = 0.029). Specifically, number of FBCTS in patients who reported moderate coffee consumption was lower than in others. In comparison with patients with moderate coffee consumption, the odds ratio (95%CI) for reporting at least 1 FBTCS per year was 1.6 (1.03-2.49) in patients who never take coffee, 1.62 (1.02-2.57) in those with rare consumption and 2.05 (1.24-3.4) in those with high consumption. Multiple ordinal logistic regression showed a trend toward an association between coffee consumption and number of FBTCS (p = 0.08). Our data suggest that effect of coffee consumption on seizures might depend on dose with potential benefits on FBTCS frequency at moderate doses. These results will have to be confirmed by prospective studies.

Identifiants

pubmed: 34929474
pii: S1525-5050(21)00747-2
doi: 10.1016/j.yebeh.2021.108486
pii:
doi:

Substances chimiques

Anticonvulsants 0
Coffee 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108486

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Julie Bourgeois-Vionnet (J)

Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and University of Lyon, Lyon, France.

Philippe Ryvlin (P)

Department of Clinical Neurosciences, Centre Hospitalo-Universitaire Vaudois, Lausanne, Switzerland.

Mad-Hélénie Elsensohn (MH)

Lyon University, Lyon, France; Équipe Biostatistique Santé, Laboratoire de Biométrie et Biologie Évolutive, CNRS UMR 5558, Villeurbanne, France; Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.

Véronique Michel (V)

Department of Neurology, Hôpital Pellegrin, Bordeaux, France.

Luc Valton (L)

Clinical Neurophysiology, Department of Neurology, University Hospital of Toulouse, CerCO CNRS UMR 5549, University of Toulouse, France.

Philippe Derambure (P)

Department of Clinical Neurophysiology, Lille University Medical Center, EA 1046, University of Lille 2, France.

Valerio Frazzini (V)

Epileptology Unit, Assistance Publique-Hôpitaux de Paris, Groupe hospitalier Pitié-Salpêtrière and Brain and Spine Institute (ICM; INSERM UMRS1127, CNRS UMR7225, UPMC University Paris 06), Paris, France.

Edouard Hirsch (E)

Department of Neurology, University Hospital of Strasbourg, Strasbourg, France.

Louis Maillard (L)

Neurology Department, University Hospital of Nancy, Nancy, France.

Fabrice Bartolomei (F)

Clinical Neurophysiology and Epileptology Department, Timone Hospital, Marseille, France.

Julien Biberon (J)

Department of Clinical Neurophysiology, INSERM U930, University Hospital of Tours, Tours, France.

Jerôme Petit (J)

La Teppe Epilepsy Center, Tain l'Hermitage, France.

Arnaud Biraben (A)

Department of Neurology, University Hospital of Rennes, Rennes, France.

Arielle Crespel (A)

Epilepsy Unit, Montpellier, France.

Pierre Thomas (P)

Neurology Department University Hospitals of Nice, Nice, France.

Martine Lemesle-Martin (M)

Department of Clinical Neurophysiology, University Hospital of Dijon, Dijon, France.

Philippe Convers (P)

Department of Neurology, University Hospital of Saint-Etienne, Saint-Etienne, France.

Mathilde Leclercq (M)

Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and University of Lyon, Lyon, France.

Sébastien Boulogne (S)

Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and University of Lyon, Lyon, France; Lyon's Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292 and Lyon 1 University, Lyon, France.

Pascal Roy (P)

Lyon University, Lyon, France; Équipe Biostatistique Santé, Laboratoire de Biométrie et Biologie Évolutive, CNRS UMR 5558, Villeurbanne, France; Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.

Sylvain Rheims (S)

Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and University of Lyon, Lyon, France; Lyon's Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292 and Lyon 1 University, Lyon, France; Epilepsy Institute, Lyon, France. Electronic address: sylvain.rheims@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH